Capricor Therapeutics Inc Total Assets
Capricor Therapeutics Inc total assets. Based on the latest financial reports, Capricor Therapeutics Inc (CAPR) holds total assets worth $326.28 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Capricor Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Capricor Therapeutics Inc (1999–2025)
Total assets of Capricor Therapeutics Inc from 1999 to 2025. This chart illustrates how Capricor Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See CAPR live share price for real-time trading data and today's change.
Capricor Therapeutics Inc - Asset Composition Analysis
Capricor Therapeutics Inc Total Assets Breakdown (December 2025)
Capricor Therapeutics Inc total assets breakdown as of December 2025. Capricor Therapeutics Inc's total assets of $326.28 Million consist of 90.7% current assets and 9.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 80.9% |
| Accounts Receivable | $59.17K | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1999–2025)
This chart illustrates how Capricor Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore CAPR working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Capricor Therapeutics Inc's current assets represent 90.7% of total assets in 2025, an increase from 0.0% in 1999.
- Cash Position: Cash and equivalents constituted 80.9% of total assets in 2025, up from 0.0% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1999.
- Asset Diversification: The largest asset category is accounts receivable at 0.0% of total assets.
Capricor Therapeutics Inc Competitors by Total Assets
Key competitors of Capricor Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
Capricor Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.42 | 6.55 | 12.20 |
| Quick Ratio | 8.42 | 6.55 | 12.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $249.45 Million | $123.91 Million | $35.56 Million |
Capricor Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Capricor Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.82 |
| Latest Market Cap to Assets Ratio | 1.46 |
| Asset Growth Rate (YoY) | 108.8% |
| Total Assets | $355.95 Million |
| Market Capitalization | $521.21 Million USD |
Valuation Analysis
Above Book Valuation: The market values Capricor Therapeutics Inc's assets above their book value (1.46x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Capricor Therapeutics Inc's assets grew by 108.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Capricor Therapeutics Inc (1999–2025)
The table below shows the annual total assets of Capricor Therapeutics Inc from 1999 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $355.95 Million | +108.79% |
| 2024-12-31 | $170.48 Million | +190.26% |
| 2023-12-31 | $58.73 Million | +17.25% |
| 2022-12-31 | $50.09 Million | +21.21% |
| 2021-12-31 | $41.33 Million | +19.39% |
| 2020-12-31 | $34.62 Million | +211.50% |
| 2019-12-31 | $11.11 Million | +20.19% |
| 2018-12-31 | $9.25 Million | -43.18% |
| 2017-12-31 | $16.27 Million | -13.19% |
| 2016-12-31 | $18.75 Million | +16.66% |
| 2015-12-31 | $16.07 Million | +17.88% |
| 2014-12-31 | $13.63 Million | +146.16% |
| 2013-12-31 | $5.54 Million | +2.11% |
| 2012-12-31 | $5.42 Million | +295.26% |
| 2011-12-31 | $1.37 Million | -62.57% |
| 2010-12-31 | $3.67 Million | +1.28% |
| 2009-12-31 | $3.62 Million | -43.75% |
| 2008-12-31 | $6.44 Million | -62.34% |
| 2007-12-31 | $17.09 Million | +406788.76% |
| 2006-12-31 | $4.20K | +1394.66% |
| 2005-12-31 | $281.00 | -55.75% |
| 2004-12-31 | $635.00 | -41.15% |
| 2003-12-31 | $1.08K | +4216.00% |
| 2002-12-31 | $25.00 | -89.71% |
| 2001-12-31 | $243.00 | -98.30% |
| 2000-12-31 | $14.26K | +4939.22% |
| 1999-12-31 | $283.00 | -- |
About Capricor Therapeutics Inc
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treat… Read more